Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms - PubMed
3 hours ago
- #MDS/MPN
- #combination therapy
- #clinical trial
- Phase 2 trial of ruxolitinib and azacitidine in MDS/MPN showed 58% objective response rate.
- Median overall survival was 26.7 months, with 5-year OS at 33%.
- Treatment had manageable safety, with anemia and thrombocytopenia as common adverse events.